Drug Supply Chain Management: A Comprehensive Review of Pharmaceutical Distribution, Inventory Optimization, Digital Transformation, and Emerging Challenge

Yuvraj Singh[1], Ritu[2]
[1]*Research Scholar, BDM Colleege of pharmacy, Chhuchhakwas, Jhajjar, Haryana- 124106*
[2]*Assistant Professor, BDM Colleege of pharmacy, Chhuchhakwas, Jhajjar, Haryana- 124106*

***Abstract*—Pharmaceutical supply chain management is a critical component of the healthcare system, ensuring the timely availability, quality, safety, and affordability of medicines from manufacturers to end users. It involves several interconnected processes, including raw material procurement, pharmaceutical manufacturing, packaging, warehousing, inventory management, transportation, distribution, and dispensing. This review provides an overview of the major stages of pharmaceutical supply chain management, inventory control techniques, cold-chain management, quality assurance practices, and regulatory requirements. It also discusses key challenges affecting pharmaceutical supply chains, including counterfeit and substandard medicines, drug shortages, inadequate storage facilities, temperature fluctuations, rising operational costs, regulatory complexities, and dependence on imported active pharmaceutical ingredients. Furthermore, the review explores emerging technologies such as artificial intelligence, the Internet of Things, block-chain, radio-frequency identification, big data analytics, and cloud computing, which have the potential to improve supply chain visibility, traceability, forecasting, and operational efficiency. Special emphasis is given to the Indian pharmaceutical supply chain, its current developments, government initiatives, and opportunities for improvement. The review also highlights strategies for strengthening procurement, inventory management, logistics, risk assessment, and sustainable distribution practices. Overall, the integration of advanced technologies, effective regulatory frameworks, stakeholder collaboration, and sustainable management strategies can contribute to developing a resilient, transparent, and efficient pharmaceutical supply chain, ultimately improving access to safe, effective, and affordable medicines.**

***Index Terms*—Drug distribution; Inventory management; Cold-chain management; Pharmaceutical logistics; Supply chain challenges; Artificial intelligence**

I. INTRODUCTION

1.1. Definition and Concept of Drug Supply Chain Management

Drug supply chain management (DSCM) is an integrated process involving the planning, procurement, manufacturing, storage, transportation, distribution, and delivery of pharmaceutical products from raw material suppliers to the final consumer or patient. It encompasses the coordinated management of materials, financial resources, information, and services among different stakeholders, including active pharmaceutical ingredient (API) manufacturers, pharmaceutical formulation companies, wholesalers, distributors, hospitals, pharmacies, and healthcare institutions. The primary objective of drug supply chain management is to ensure that the right medicine reaches the right patient, in the appropriate quantity and quality, at the right time and place, and at an affordable cost (Jaberidoost et al., 2013).

According to Uthayakumar and Priyan (2013), pharmaceutical supply chain management involves the integration of activities associated with the flow and transformation of pharmaceutical products, beginning with raw material procurement and continuing through manufacturing and distribution to the end user. Unlike conventional supply chains, pharmaceutical supply chains require strict quality control, regulatory compliance, product traceability, and appropriate storage and transportation conditions because the

quality and stability of medicines directly influence patient safety and therapeutic outcomes. Furthermore, Yousefi and Alibabaei (2015) emphasized that effective information flow and communication among supply chain stakeholders are essential for improving coordination, operational efficiency, and decision-making. The pharmaceutical supply chain can therefore be considered a multidimensional system consisting of three major interconnected flows: material flow, information flow, and financial flow. Material flow involves the movement of raw materials and finished pharmaceutical products, information flow includes demand forecasting, procurement records, inventory status, and product traceability, whereas financial flow involves payments, procurement costs, and other commercial transactions. Effective integration of these three flows is essential for maintaining supply chain efficiency, transparency, and reliability (Yousefi and Alibabaei, 2015).

1.2. Historical Development of Pharmaceutical Supply Chain Systems

The development of pharmaceutical supply chain management has evolved considerably with advancements in manufacturing technologies, transportation systems, information technology, and global trade. Initially, pharmaceutical distribution systems were relatively simple and primarily focused on local procurement, manufacturing, storage, and delivery of medicines. Pharmaceutical manufacturers and healthcare institutions generally managed their inventories independently, with limited coordination and information exchange between different supply chain participants.

During the 1960s and 1970s, supply chain activities were predominantly inventory-oriented, with greater emphasis on stock maintenance, warehousing, and financial control. Subsequently, during the 1970s and 1980s, organizations gradually shifted towards demand-oriented approaches, focusing on customer requirements, product availability, and improved distribution strategies. The development of integrated supply chain management approaches encouraged organizations to coordinate procurement, production, inventory, and distribution activities rather than managing them as independent operations (Yousefi and Alibabaei, 2015). During the 1990s, globalization and the expansion of international pharmaceutical markets increased the complexity of drug manufacturing and distribution networks. Pharmaceutical companies increasingly adopted computerized inventory management systems, enterprise resource planning (ERP), electronic data interchange (EDI), and advanced logistics management approaches to improve coordination and operational performance. These developments facilitated better communication between manufacturers, suppliers, distributors, and healthcare institutions.

In the early twenty-first century, pharmaceutical supply chains underwent further transformation through digitalization, automation, and international regulatory harmonization. The introduction of electronic tracking systems, barcoding, serialization, and improved quality management practices strengthened product identification and traceability. The World Health Organization (WHO) also established and updated Good Distribution Practices (GDP) guidelines to support the maintenance of pharmaceutical product quality and identity throughout procurement, storage, transportation, and distribution processes (WHO, 2006; WHO, 2020). More recently, the COVID-19 pandemic highlighted the vulnerabilities associated with global pharmaceutical supply chains, particularly dependence on limited suppliers, international transportation disruptions, and shortages of essential medicines. Consequently, modern pharmaceutical supply chain systems are increasingly incorporating artificial intelligence (AI), blockchain technology, the Internet of Things (IoT), big data analytics, and predictive inventory management to improve transparency, resilience, and responsiveness (Mendoza, 2021; Wadhwa et al., 2024).

1.3. Importance of Supply Chain Management in the Pharmaceutical Industry

Pharmaceutical supply chain management plays a fundamental role in the effective functioning of the pharmaceutical industry by ensuring the continuous movement of medicines from manufacturers to healthcare providers and patients. The pharmaceutical sector involves multiple interconnected activities, including raw material sourcing, drug development, manufacturing, quality assurance, packaging, warehousing, transportation, and distribution. Proper coordination of these activities is essential for reducing operational inefficiencies, minimizing

product losses, and maintaining uninterrupted medicine availability (Jaberidoost et al., 2013). An efficient pharmaceutical supply chain provides several important benefits to the pharmaceutical industry. It facilitates accurate demand forecasting, optimizes inventory levels, improves procurement practices, reduces unnecessary storage and transportation costs, and supports timely distribution of medicines. Effective inventory management is particularly important because excessive stockholding may increase storage expenses and product expiry, whereas inadequate inventory may result in medicine shortages and interruptions in patient treatment (Uthayakumar and Priyan, 2013).

Furthermore, supply chain management strengthens coordination between pharmaceutical manufacturers, suppliers, wholesalers, distributors, and healthcare institutions. The integration of information systems enables organizations to monitor product movement, maintain inventory records, identify supply disruptions, and improve operational decision-making. According to Yousefi and Alibabaei (2015), an effective information management system is an important component of pharmaceutical supply chain integration because information exchange supports coordination among different stakeholders. In addition, pharmaceutical supply chain management contributes to regulatory compliance and product quality assurance by supporting appropriate storage conditions, transportation monitoring, documentation, and product traceability. The implementation of Good Manufacturing Practices (GMP), Good Storage Practices (GSP), and Good Distribution Practices (GDP) helps maintain pharmaceutical product quality throughout the supply chain. Therefore, an efficient supply chain is not only an operational requirement but also an essential component of pharmaceutical quality management and healthcare delivery (WHO, 2020).

1.4. Role of Supply Chain Management in Ensuring Drug Availability, Quality, Safety, and Affordability

The availability, quality, safety, and affordability of medicines are important determinants of effective healthcare delivery. Drug supply chain management contributes to these factors through the systematic coordination of procurement, inventory management, storage, transportation, distribution, and monitoring activities. An efficient supply chain ensures that pharmaceutical products are available in the required quantities and are delivered to healthcare facilities without unnecessary delays (WHO, 2015).

Drug availability: Effective supply chain management helps maintain the continuous availability of essential medicines by improving demand forecasting, procurement planning, stock monitoring, and distribution activities. Proper inventory control minimizes both overstocking and stock-outs, thereby reducing interruptions in patient treatment. The WHO medicines management cycle identifies selection, quantification, forecasting, procurement, storage, and distribution as important components of an effective medicines supply system (WHO, 2015).

Drug quality: Maintaining pharmaceutical product quality requires appropriate control throughout manufacturing, storage, and distribution. Exposure to unsuitable temperature, humidity, light, and other environmental conditions may negatively affect the stability and quality of pharmaceutical formulations. Implementation of GMP, GDP, and appropriate storage practices helps preserve the identity, strength, quality, and purity of medicines. The WHO emphasizes that quality assurance should extend beyond manufacturing operations to all stages of the pharmaceutical distribution chain (WHO, 2020).

Drug safety: An effective supply chain contributes to patient safety by reducing the risk of counterfeit, falsified, contaminated, expired, and improperly stored medicines entering the distribution network. Product identification, batch tracking, serialization, documentation, and recall management are important mechanisms for identifying and controlling potentially unsafe pharmaceutical products. Jaberidoost et al. (2013) highlighted that supply chain risks can adversely affect medicine quality, quantity, and timely delivery, ultimately threatening patient access to essential medicines.

Drug affordability: Efficient pharmaceutical procurement, inventory optimization, supplier selection, and transportation management can reduce operational expenditure and unnecessary distribution costs. These improvements may contribute to lower medicine procurement costs and better utilization of healthcare resources. Moreover, transparent procurement systems and effective public-sector distribution mechanisms can improve access to affordable essential medicines, particularly among economically disadvantaged populations (WHO,

2015; Wadhwa et al., 2024). Thus, an integrated pharmaceutical supply chain is essential for ensuring that medicines remain available, maintain their intended quality and safety, and reach patients at reasonable costs.

1.5. Global Pharmaceutical Supply Chain Scenario

The global pharmaceutical supply chain represents a complex international network involving raw material suppliers, API manufacturers, formulation development companies, contract manufacturing organizations, packaging industries, logistics providers, wholesalers, distributors, hospitals, and retail pharmacies. Pharmaceutical manufacturing and distribution activities are increasingly interconnected across geographical boundaries, with raw materials, intermediates, and finished pharmaceutical products frequently moving between different countries before reaching the final consumer.

Globalization has expanded pharmaceutical manufacturing capabilities and international trade, allowing pharmaceutical companies to obtain raw materials, manufacturing services, and distribution support from different geographical regions. However, this interconnected structure has also increased supply chain complexity and exposure to international disruptions. Supplier dependency, geopolitical instability, transportation delays, regulatory differences, economic fluctuations, and unexpected increases in demand may adversely affect the continuity of pharmaceutical supplies (Jaberidoost et al., 2013; Mendoza, 2021).

The COVID-19 pandemic further demonstrated the vulnerability of international pharmaceutical supply networks. Restrictions on international transportation, manufacturing interruptions, export limitations, and increased demand for essential medicines and healthcare products affected pharmaceutical production and distribution in several countries. These circumstances highlighted the importance of supplier diversification, strategic inventory management, domestic manufacturing capabilities, and risk-based supply chain planning. Another important global concern is the increasing requirement for pharmaceutical product traceability and quality assurance. The international movement of medicines requires effective regulatory coordination, appropriate storage conditions, and compliance with distribution standards to prevent substandard and falsified products from entering legitimate supply networks. The WHO has established international guidelines for good storage and distribution practices to support the maintenance of product quality, integrity, and traceability throughout the pharmaceutical supply chain (WHO, 2020). In recent years, digital transformation has emerged as an important approach for strengthening global pharmaceutical supply chain performance. Technologies such as artificial intelligence, blockchain, IoT-based monitoring, and advanced data analytics are increasingly being investigated for demand forecasting, inventory optimization, temperature monitoring, product authentication, and real-time tracking. These technological developments may improve supply chain visibility, operational efficiency, and resilience against unexpected disruptions (Mendoza, 2021).

1.6. Importance of Efficient Drug Supply Chains in Developing Countries, Particularly India

Efficient pharmaceutical supply chain management is particularly important in developing countries because healthcare systems frequently face challenges related to inadequate infrastructure, limited financial resources, insufficient storage facilities, weak distribution networks, and unequal access to essential medicines. These challenges may lead to frequent stock-outs, delayed procurement, poor inventory control, and interruptions in the availability of essential pharmaceutical products. Jaberidoost et al. (2013) identified supplier-related, financial, organizational, logistical, and regulatory factors as important sources of pharmaceutical supply chain vulnerability, particularly in developing healthcare systems.

India represents an important example of a developing pharmaceutical market with a substantial domestic manufacturing base and an extensive network of pharmaceutical manufacturers, wholesalers, distributors, hospitals, and retail pharmacies. The Indian pharmaceutical industry plays a significant role in supplying generic medicines to domestic and international markets. However, maintaining an uninterrupted supply of medicines across different geographical regions remains challenging because of differences in healthcare infrastructure, procurement mechanisms, storage facilities, and distribution capabilities. Wadhwa et al., (2024), in their systematic review of essential medicine availability and

utilization in India, reported considerable variations in medicine availability across different states. The review identified availability levels ranging from approximately 17% to 51% in the assessed studies, with reported stock-out periods ranging from 4 to 14 weeks. The authors highlighted inadequate procurement planning, inefficient distribution mechanisms, governance-related issues, and insufficient inventory management as important barriers to the availability and utilization of essential medicines.

Another significant concern for India's pharmaceutical supply chain is its dependence on imported active pharmaceutical ingredients and drug intermediates. According to the Department of Pharmaceuticals, Government of India (2026), India imported approximately USD 4.35 billion worth of APIs, bulk drugs, and drug intermediates during the financial year 2024–2025, with China accounting for approximately 73.7% of these imports. Such import concentration may expose domestic pharmaceutical manufacturers to international supply disruptions, geopolitical uncertainties, and raw material price fluctuations. To strengthen domestic pharmaceutical manufacturing and reduce import dependency, the Government of India has introduced initiatives such as the Production Linked Incentive (PLI) Scheme for bulk drugs and the Scheme for Promotion of Bulk Drug Parks. These initiatives aim to encourage domestic manufacturing of critical APIs, key starting materials, and drug intermediates, thereby improving the resilience of the pharmaceutical supply chain (Department of Pharmaceuticals, Government of India, 2026).

Furthermore, improving public-sector medicine procurement and distribution systems is essential for strengthening healthcare delivery in India. Government-supported initiatives such as the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) aim to improve access to quality generic medicines at affordable prices. Efficient procurement, centralized warehousing, digital inventory monitoring, transparent distribution systems, and improved last-mile delivery mechanisms can further strengthen medicine availability, particularly in rural and underserved regions. Therefore, the development of an efficient, transparent, technologically advanced, and resilient pharmaceutical supply chain is essential for improving medicine availability, reducing healthcare expenditure, strengthening domestic manufacturing, and supporting equitable access to essential medicines in India.

II. OVERVIEW OF THE PHARMACEUTICAL SUPPLY CHAIN

The pharmaceutical supply chain is a complex and interconnected network responsible for the procurement of raw materials, manufacturing, packaging, storage, transportation, and distribution of pharmaceutical products from manufacturers to the final consumers. It involves the coordinated activities of multiple stakeholders, including raw material suppliers, API manufacturers, pharmaceutical companies, logistics providers, wholesalers, distributors, hospitals, and retail pharmacies. The primary purpose of this system is to ensure the continuous availability of safe, effective, and quality-assured medicines while maintaining appropriate storage conditions and regulatory compliance throughout the distribution process (Jaberidoost et al., 2013; Uthayakumar and Priyan, 2013).

Unlike conventional commercial supply chains, pharmaceutical supply chains require strict quality assurance, product traceability, temperature control, and regulatory monitoring because any compromise in product quality may directly affect patient health and treatment outcomes. The integration of material, information, and financial flows is therefore essential for improving operational efficiency, minimizing supply disruptions, and ensuring timely access to medicines (Yousefi and Alibabaei, 2015).

2.1. Major Components of the Pharmaceutical Supply Chain

The pharmaceutical supply chain consists of several interconnected components, each performing specific functions to maintain the continuous movement of pharmaceutical products from their initial production stages to patient delivery.

Raw material suppliers: Raw material suppliers provide essential pharmaceutical ingredients, including chemical compounds, excipients, solvents, and other materials required for drug manufacturing. The quality and reliability of raw material suppliers are important for maintaining product consistency, manufacturing efficiency, and regulatory compliance.

Active Pharmaceutical Ingredient (API) manufacturers: API manufacturers produce the pharmacologically active substances responsible for

the therapeutic effects of medicines. APIs undergo appropriate quality testing to ensure their identity, purity, potency, and compliance with established pharmaceutical standards before being supplied to formulation manufacturers.

Pharmaceutical formulation manufacturers: These manufacturers convert APIs and excipients into finished dosage forms, including tablets, capsules, injections, syrups, ointments, and other pharmaceutical preparations. Manufacturing operations are performed under established Good Manufacturing Practices (GMP) to ensure product quality, safety, and consistency.

Packaging and labeling units: Packaging and labeling units are responsible for protecting pharmaceutical products against physical, chemical, and environmental deterioration. They also provide essential product information, including drug composition, batch number, manufacturing date, expiry date, storage instructions, and manufacturer details. Proper packaging and labeling support product identification, traceability, and patient safety.

Warehouses and distribution centers: Warehouses and distribution centers serve as intermediate storage and handling facilities between manufacturers and distribution channels. They maintain appropriate environmental conditions, manage inventory levels, monitor product expiry dates, and facilitate the systematic movement of medicines. Good Storage Practices (GSP) are essential for maintaining pharmaceutical product quality during storage.

Wholesalers and distributors: Wholesalers and distributors purchase pharmaceutical products from manufacturers and supply them to hospitals, pharmacies, healthcare institutions, and retail medical stores. They play an important role in managing product availability, transportation, inventory distribution, and regional medicine accessibility.

Hospitals, pharmacies, and retail medical stores: These institutions represent the major points of pharmaceutical product delivery within the healthcare system. Hospital pharmacies supply medicines to admitted and outpatient patients, whereas retail pharmacies provide pharmaceutical products directly to consumers based on valid prescriptions and applicable regulations.

Patients and end users: Patients represent the final recipients of pharmaceutical products and the ultimate beneficiaries of the supply chain. Timely availability, appropriate storage, product quality, affordability, and safe dispensing are essential to ensure effective treatment and better healthcare outcomes.

III. STRUCTURE AND OPERATIONAL FLOW OF THE PHARMACEUTICAL SUPPLY CHAIN

The pharmaceutical supply chain follows a systematic operational structure through which medicines move from raw material procurement to final patient delivery. This process involves the coordination of manufacturing, quality control, inventory management, warehousing, transportation, and distribution activities. An effective operational flow ensures that pharmaceutical products are delivered in the required quantities, within specified timeframes, and under appropriate storage and handling conditions (Uthayakumar and Priyan, 2013).




Figure 1. Structure and Operational Flow of the Pharmaceutical Supply Chain

The major operational stages of the pharmaceutical supply chain are described below:

1. Raw material procurement: The process begins with the identification and procurement of APIs, excipients, solvents, and packaging materials from qualified suppliers. Supplier selection and material quality assessment are essential for ensuring uninterrupted manufacturing operations.
2. Pharmaceutical manufacturing: Procured materials are processed into finished pharmaceutical dosage forms through appropriate manufacturing procedures. Quality control and quality assurance activities are performed to ensure compliance with established specifications and GMP requirements.
3. Packaging and labeling: Finished pharmaceutical products undergo primary and secondary packaging, followed by appropriate labeling. Product identification, batch coding, and expiry information are incorporated to support traceability and safe handling.
4. Warehousing and inventory management: Packaged medicines are transferred to warehouses and distribution centers, where they are stored under suitable environmental conditions. Inventory management techniques, including FIFO and FEFO, are applied to minimize product expiry and maintain stock availability.
5. Transportation and distribution: Pharmaceutical products are transported from manufacturing facilities to wholesalers, distributors, hospitals, and retail pharmacies. Appropriate transportation conditions and monitoring systems are maintained to preserve product quality during movement.
6. Dispensing and patient delivery: The final stage involves the supply and dispensing of medicines through hospitals, healthcare institutions, and retail pharmacies. Medicines are delivered to patients with appropriate dispensing instructions and storage guidance.
7. Reverse logistics and product recall: Expired, damaged, defective, or recalled pharmaceutical products are identified and returned through appropriate reverse distribution channels. This process helps prevent unsafe medicines from reaching patients and supports regulatory compliance.

The overall pharmaceutical supply chain follows a continuous cycle of material movement, information exchange, and financial transactions. Proper coordination among all stages is necessary to minimize delays, reduce operational costs, and maintain uninterrupted medicine availability (Jaberidoost et al., 2013; WHO, 2020).

IV. KEY STAKEHOLDERS AND THEIR RESPONSIBILITIES

Pharmaceutical supply chain management involves several stakeholders who contribute to the production, quality assurance, storage, transportation, distribution, and delivery of medicines. Each stakeholder performs specific responsibilities that collectively determine the efficiency, reliability, and effectiveness of the pharmaceutical supply chain. Coordination and information sharing among these participants are essential for maintaining product quality, preventing supply disruptions, and ensuring timely availability of medicines (Yousefi and Alibabaei, 2015).

Table 1. Stakeholders and Their Responsibilities

Stakeholders	Major responsibilities
Raw material suppliers	Supply APIs, excipients, solvents, and packaging materials according to established quality specifications.
API manufacturers	Manufacture active pharmaceutical ingredients and maintain their quality, purity, and regulatory compliance.
Pharmaceutical manufacturers	Produce finished dosage forms while following GMP and quality assurance requirements.
Packaging and labeling companies	Ensure appropriate packaging, product identification, labeling, and traceability.
Regulatory authorities	Establish regulatory standards, inspect facilities, monitor compliance, and control the quality and safety of medicines.
Warehousing companies	Maintain appropriate storage conditions, inventory records, and stock management systems.
Logistics and transportation providers	Ensure safe and timely transportation of pharmaceutical products under suitable environmental conditions.
Wholesalers and distributors	Manage bulk procurement, storage, regional distribution, and medicine availability.

Hospitals and healthcare institutions	Procure, store, manage, and supply medicines to patients according to healthcare requirements.
Retail pharmacies	Dispense medicines, maintain stock records, and provide appropriate patient counseling.
Patients and end users	Use medicines appropriately and follow prescribed dosage and storage instructions.

Effective collaboration among these stakeholders supports transparency, accountability, regulatory compliance, and continuous medicine availability. Any disruption or failure at one stage may affect the functioning of the entire supply chain and ultimately influence patient access to essential medicines (Jaberidoost et al., 2013).

4.1. Conventional Versus Modern Pharmaceutical Supply Chain Systems

Pharmaceutical supply chain systems have gradually evolved from traditional, manually operated distribution networks to integrated and technology-driven management systems. Conventional supply chains primarily depend on manual documentation, periodic inventory assessment, traditional procurement practices, and limited information exchange between stakeholders. Although these systems support basic pharmaceutical distribution, they may experience operational limitations related to delayed information, inaccurate demand forecasting, inefficient inventory control, and limited product traceability. In contrast, modern pharmaceutical supply chain systems incorporate digital technologies, automated inventory management, real-time monitoring, data analytics, and integrated information-sharing platforms. These advancements facilitate improved coordination between manufacturers, suppliers, distributors, healthcare institutions, and pharmacies. Emerging technologies such as artificial intelligence (AI), blockchain, the Internet of Things (IoT), and radio-frequency identification (RFID) have the potential to improve product tracking, demand forecasting, inventory optimization, and supply chain transparency (Yousefi and Alibabaei, 2015).

Table 2. Comparison between conventional and modern pharmaceutical supply chain systems

Parameters	Conventional system	Modern system
Inventory management	Manual stock recording	Automated inventory management
Demand forecasting	Historical records and manual estimation	AI-based predictive analytics
Product tracking	Paper-based documentation	Barcode, RFID, and digital tracking
Information sharing	Limited and delayed communication	Real-time information exchange
Warehouse management	Manual operations	Smart warehouses and automation
Transportation monitoring	Conventional monitoring	GPS and IoT-enabled tracking
Quality monitoring	Periodic inspection	Continuous digital monitoring
Drug traceability	Limited batch-level tracking	Enhanced digital traceability
Decision-making	Experience-based decisions	Data-driven decision-making
Risk management	Reactive approach	Predictive and preventive approach
Supply chain transparency	Limited visibility	Improved end-to-end visibility
Operational efficiency	Relatively time-consuming	Improved speed and coordination

The transition towards modern pharmaceutical supply chain systems offers significant opportunities for improving operational efficiency, reducing distribution-related risks, and strengthening medicine traceability. However, implementation may be affected by high initial investment, technological limitations, cybersecurity concerns, inadequate infrastructure, and the need for trained personnel. Therefore, integrating digital technologies with established pharmaceutical quality and regulatory practices is essential for developing an efficient, reliable, and sustainable supply chain (WHO, 2020).

V. MAJOR STAGES OF DRUG SUPPLY CHAIN MANAGEMENT

The pharmaceutical supply chain consists of interconnected activities involved in the procurement, manufacturing, packaging, storage, transportation, and distribution of medicines to patients. Each stage plays an important role in maintaining product quality, safety, availability, and regulatory compliance. Effective coordination among suppliers, manufacturers, distributors, and healthcare institutions

is essential for ensuring an uninterrupted supply of medicines (Jaberidoost et al., 2013; WHO, 2020).

5.1. Raw Material Procurement

Raw material procurement involves the purchase of active pharmaceutical ingredients (APIs), excipients, solvents, and packaging materials required for pharmaceutical manufacturing. Supplier selection and qualification are important to ensure the quality, reliability, and regulatory compliance of procured materials. Vendor audits, quality assessments, and certificates of analysis help maintain the required standards and reduce procurement-related risks (Jaberidoost et al., 2013).

5.2. Pharmaceutical Manufacturing

Pharmaceutical manufacturing involves converting APIs and excipients into finished dosage forms such as tablets, capsules, injections, and syrups. Production planning, quality control (QC), and quality assurance (QA) are essential for maintaining consistent product quality. Compliance with Good Manufacturing Practices (GMP) ensures appropriate control over personnel, equipment, manufacturing processes, documentation, and product testing (WHO, 2014).

5.3. Drug Packaging and Labeling

Packaging protects pharmaceutical products from contamination, moisture, light, and physical damage. It includes primary, secondary, and tertiary packaging. Product labeling provides essential information such as product name, strength, batch number, manufacturing date, expiry date, and storage instructions. Barcoding and serialization improve product identification, traceability, and protection against falsified medicines (WHO, 2020).

5.4. Pharmaceutical Warehousing and Storage

Pharmaceutical warehousing involves the systematic receipt, storage, handling, and dispatch of medicines under appropriate environmental conditions. Temperature, humidity, cleanliness, and product segregation must be properly maintained to preserve product quality. Warehouse Management Systems (WMS), inventory monitoring, and FEFO practices help reduce expiry-related losses and improve stock control (WHO, 2020).

5.5. Drug Transportation and Distribution

Transportation and distribution involve the movement of medicines from manufacturing facilities to wholesalers, distributors, hospitals, and retail pharmacies. Proper transportation arrangements, suitable packaging, route planning, and temperature monitoring are essential for maintaining product quality. Efficient logistics management also supports timely delivery and reduces distribution costs (WHO, 2010; Jaberidoost et al., 2013).

5.6. Dispensing and Delivery to Patients

Dispensing and delivery represent the final stage of the pharmaceutical supply chain. Medicines are supplied through hospital pharmacies, retail pharmacies, and healthcare institutions. Pharmacists play an important role in prescription verification, medicine dispensing, patient counseling, and appropriate storage. Effective coordination between suppliers and healthcare facilities improves medicine availability and supports continuity of treatment (Uthayakumar and Priyan, 2013).

VI. INVENTORY MANAGEMENT IN THE PHARMACEUTICAL INDUSTRY

Inventory management involves the systematic planning, procurement, storage, and control of pharmaceutical products to maintain adequate stock while minimizing costs, wastage, and shortages. It is particularly important in the pharmaceutical industry because medicines have different costs, consumption patterns, expiry dates, and clinical importance. Appropriate inventory techniques help ensure medicine availability and improve financial resource utilization (Uthayakumar and Priyan, 2013; Priyan and Uthayakumar, 2014).

6.1. ABC Analysis

ABC analysis classifies medicines according to their annual consumption value. Category A includes high-value items requiring strict control, Category B includes medium-value items requiring moderate monitoring, and Category C includes low-value items requiring comparatively simple control. This technique helps prioritize procurement and control inventory expenditure (Uthayakumar and Priyan, 2013).

6.2. VED Analysis

VED analysis classifies medicines according to their clinical importance. Vital medicines are essential for saving lives, Essential medicines are required for important healthcare needs, and Desirable medicines are useful but their temporary absence may have comparatively limited clinical consequences. This method helps prioritize medicines according to therapeutic requirements (Priyan and Uthayakumar, 2014).

6.3. ABC–VED Matrix Analysis

ABC–VED analysis combines financial value and clinical importance to establish inventory priorities. It helps identify medicines that require strict managerial control because of their high cost or clinical significance. This method is particularly useful in hospital pharmacies and healthcare institutions for improving procurement and stock management (Uthayakumar and Priyan, 2013).

6.4. Economic Order Quantity (EOQ)

Economic Order Quantity is a technique used to determine the optimal quantity of medicines or materials to be ordered while minimizing ordering and holding costs. It considers annual demand, ordering cost, and inventory holding cost.

\ [EOQ=\sqrt{\frac{2DS} {H}} \]

Where D represents annual demand, S represents ordering cost per order, and H represents annual holding cost per unit. EOQ supports systematic procurement planning and helps avoid unnecessary inventory accumulation (Uthayakumar and Priyan, 2013).

6.5. Minimum and Maximum Stock Levels

Minimum and maximum stock levels define the acceptable lower and upper limits of inventory. Minimum stock levels help prevent shortages, whereas maximum stock levels prevent excessive purchasing and unnecessary storage costs. These levels should be determined according to consumption, supplier lead time, and medicine requirements (Priyan and Uthayakumar, 2014).

6.6. Safety Stock Management

Safety stock refers to additional inventory maintained to manage unexpected increases in demand, supplier delays, and transportation disruptions. It is particularly important for essential and life-saving medicines. Appropriate safety stock planning improves supply continuity, although excessive stock may increase storage costs and expiry-related losses (Jaberidoost et al., 2013).

6.7. First Expiry, First Out (FEFO)

FEFO is an inventory rotation method in which medicines with the earliest expiry dates are issued first, regardless of their receipt dates. It helps minimize expiry-related wastage and ensures that medicines with shorter remaining shelf lives are distributed appropriately (WHO, 2020).

6.8. First In, First Out (FIFO)

FIFO is a stock rotation technique in which products received first are issued first. It supports systematic inventory movement and reduces prolonged storage. However, FEFO is generally preferred for medicines when their expiry dates differ (WHO, 2020).

6.9. Prevention of Drug Shortages and Overstocking

Effective inventory management reduces drug shortages and overstocking through accurate demand forecasting, regular stock monitoring, supplier coordination, and computerized inventory systems. Combining ABC–VED analysis, safety stock, and FEFO practices can improve stock availability and reduce financial losses (Uthayakumar and Priyan, 2013; Jaberidoost et al., 2013).

Table 3. Major inventory management techniques

Technique	Main purpose
ABC analysis	Financial classification
VED analysis	Clinical prioritization
ABC–VED matrix	Combined inventory control
EOQ	Optimal order quantity
Minimum–maximum levels	Stock level regulation
Safety stock	Prevention of unexpected shortages
FEFO	Expiry-based stock rotation
FIFO	Receipt-based stock rotation

VII. COLD CHAIN MANAGEMENT IN PHARMACEUTICALS

Cold chain management involves the storage, handling, transportation, and distribution of temperature-sensitive pharmaceutical products under specified environmental conditions. It is essential for maintaining the stability, potency, and quality of

vaccines, insulin, biological products, and other temperature-sensitive medicines. WHO guidelines emphasize appropriate storage equipment, temperature monitoring, transportation procedures, and management of temperature excursions (WHO, 2011; WHO, 2015).

7.1. Concept and Importance of Pharmaceutical Cold Chains

A pharmaceutical cold chain is an integrated system designed to maintain the required temperature conditions from manufacturing to the final point of use. It includes refrigerated storage facilities, temperature-controlled vehicles, insulated containers, monitoring devices, and trained personnel. Proper cold chain management helps prevent product degradation and maintains medicine quality (WHO, 2011).

7.2. Temperature-Sensitive Drugs and Biological Products

Temperature-sensitive products include vaccines, insulin, monoclonal antibodies, recombinant proteins, and selected biological preparations. These products may require refrigerated, frozen, or ultra-low-temperature storage depending on their formulation and manufacturer's recommendations. Maintaining the specified temperature range is essential for preserving their quality (WHO, 2015).

7.3. Vaccine and Insulin Storage and Transportation

Many routine vaccines require storage between 2–8°C, although storage requirements vary according to the specific vaccine. Insulin preparations also generally require refrigeration before use, as specified by the manufacturer. Appropriate insulated packaging and temperature monitoring are necessary during transportation to prevent exposure to excessive heat or freezing (WHO, 2011; WHO, 2015).

7.4. Cold Chain Monitoring Systems

Cold chain monitoring systems include digital data loggers, temperature indicators, wireless sensors, and automated monitoring platforms. These systems continuously record temperature conditions and can generate alerts when deviations occur. Their use improves monitoring accuracy and supports timely corrective action (WHO, 2015).

7.5. Temperature Excursions and Their Management

A temperature excursion occurs when a pharmaceutical product is exposed to temperatures outside its specified storage range. Equipment failure, power interruptions, and transportation delays are common causes. Affected products should be identified, segregated, documented, and assessed using available stability information before a decision is made regarding their suitability for use (WHO, 2015).

7.6. Refrigerated Transportation and Packaging

Refrigerated transportation uses temperature-controlled vehicles, insulated containers, and qualified packaging systems to maintain product stability. Packaging selection should consider transport duration, environmental conditions, and product-specific temperature requirements. Regular equipment maintenance and temperature monitoring are essential for reliable transportation (WHO, 2011).

7.7. Challenges in Cold Chain Logistics

Major cold chain challenges include inadequate refrigeration facilities, electricity interruptions, high transportation costs, equipment failure, and insufficient trained personnel. These problems may be more significant in rural and remote regions. Improved infrastructure, preventive maintenance, remote temperature monitoring, and staff training can strengthen cold chain performance (WHO, 2015).

VIII. QUALITY ASSURANCE AND REGULATORY REQUIREMENTS

Quality assurance and regulatory compliance ensure that pharmaceutical products maintain their identity, strength, quality, purity, and safety throughout the supply chain. Effective quality management helps prevent contamination, product degradation, falsification, and distribution of unsuitable medicines. WHO guidelines emphasize appropriate quality systems, documentation, risk management, and controlled storage and distribution procedures (WHO, 2014; WHO, 2020).

8.1. Good Manufacturing Practices (GMP)

Good Manufacturing Practices are standards that ensure pharmaceutical products are consistently manufactured and controlled according to established quality requirements. GMP covers personnel training,

equipment, premises, sanitation, production processes, quality testing, validation, and documentation (WHO, 2014).

8.2. Good Distribution Practices (GDP)

Good Distribution Practices ensure that pharmaceutical products are appropriately handled, stored, transported, and distributed. They include supplier qualification, transportation controls, product traceability, documentation, and management of returned and recalled products (WHO, 2010).

8.3. Good Storage Practices (GSP)

Good Storage Practices involve maintaining suitable environmental conditions during pharmaceutical storage. Important requirements include temperature and humidity monitoring, cleanliness, pest control, proper segregation, stock rotation, and appropriate handling of expired or damaged medicines (WHO, 2020).

8.4. Quality Risk Management

Quality risk management involves identifying, evaluating, controlling, and reviewing risks that may affect pharmaceutical product quality. Tools such as Failure Mode and Effects Analysis (FMEA) and root-cause analysis can help identify supply chain weaknesses and support corrective and preventive actions (WHO, 2014).

8.5. Standard Operating Procedures (SOPs)

Standard Operating Procedures are documented instructions used to maintain consistency in pharmaceutical activities. Common SOPs cover material receiving, storage, temperature monitoring, inventory management, transportation, product returns, and recall procedures. Regular review and staff training are essential for effective implementation (WHO, 2020).

8.6. Documentation and Record Keeping

Documentation provides evidence that pharmaceutical activities are performed according to approved procedures. Important records include purchase orders, batch details, certificates of analysis, temperature logs, stock registers, distribution documents, and recall reports. Accurate records support traceability, regulatory inspections, and quality investigations (WHO, 2010).

8.7. Product Recall Management

Product recall involves the removal of defective, unsafe, contaminated, or otherwise unsuitable medicines from distribution channels. An effective recall system requires batch identification, traceability, stakeholder communication, product segregation, and documented follow-up procedures (WHO, 2010; WHO, 2020).

8.8. Pharmacovigilance and Supply Chain-Related Product Quality Concerns

Pharmacovigilance involves the detection, assessment, and prevention of adverse effects and other medicine-related problems. Improper storage, contamination, falsified medicines, and product degradation may affect medicine safety and effectiveness. Reporting suspected adverse events and product quality defects supports patient safety and regulatory decision-making (WHO, 2024).

8.9. Regulatory Requirements in India and International Markets

In India, pharmaceutical manufacturing, import, sale, and distribution are regulated primarily under the Drugs and Cosmetics Act, 1940, and Drugs Rules, 1945. The Central Drugs Standard Control Organisation (CDSCO) and State Drug Control Authorities play important roles in regulatory oversight. International pharmaceutical distribution must also comply with applicable WHO guidelines and the regulations of the importing and exporting countries (Government of India, 1940; Government of India, 1945; WHO, 2020).

IX. MAJOR CHALLENGES IN PHARMACEUTICAL SUPPLY CHAIN MANAGEMENT

Pharmaceutical supply chain management faces several challenges related to product quality, procurement, logistics, infrastructure, regulatory compliance, and global supply disruptions. These challenges may affect medicine availability, affordability, and patient safety. Identifying supply chain risks and implementing appropriate control strategies are essential for maintaining an efficient and resilient distribution network (Jaberidoost et al., 2013).

9.1. Counterfeit and Substandard Medicines
Counterfeit and substandard medicines are major public health concerns. Falsified products may contain incorrect ingredients or misrepresent their source, while substandard medicines fail to meet established quality specifications. Supplier verification, product authentication, regulatory monitoring, and improved traceability can help reduce these risks (WHO, 2024).

9.2. Drug Shortages and Supply Disruptions
Drug shortages may occur due to manufacturing problems, raw material shortages, supplier failure, increased demand, or transportation delays. Such disruptions can interrupt treatment and increase healthcare costs. Supplier diversification, safety stock, and improved demand forecasting can help minimize their impact (Jaberidoost et al., 2013).

9.3. Poor Inventory Management
Inaccurate forecasting, manual stock records, poor procurement planning, and inadequate stock monitoring may cause shortages and overstocking. Computerized inventory systems, ABC–VED analysis, and regular stock audits can improve inventory accuracy (Uthayakumar and Priyan, 2013).

9.4. Inadequate Storage Facilities
Poor warehouse infrastructure, unsuitable temperature conditions, humidity, and improper product segregation may affect medicine quality. Qualified storage facilities and regular environmental monitoring are necessary to maintain pharmaceutical product integrity (WHO, 2020).

9.5. Temperature Fluctuations During Transportation
Temperature fluctuations may reduce the stability of vaccines, insulin, and biological products. Refrigeration failures, inadequate packaging, and transportation delays are common causes. Temperature-controlled vehicles and monitoring devices can help prevent such problems (WHO, 2011).

9.6. High Transportation and Operational Costs
Fuel, warehousing, labor, packaging, refrigeration, and inventory holding contribute to pharmaceutical distribution costs. Route optimization, efficient vehicle utilization, and improved logistics planning can reduce unnecessary expenditure (Jaberidoost et al., 2013).

9.7. Lack of Supply Chain Transparency
Limited information sharing among manufacturers, distributors, wholesalers, and healthcare institutions makes product tracking and shortage identification difficult. Digital information systems, RFID, and blockchain may improve supply chain visibility and traceability (Saeed et al., 2022).

9.8. Regulatory and Compliance Difficulties
Different regulatory requirements, documentation procedures, and quality standards may create difficulties for pharmaceutical companies, particularly those involved in international trade. Regular audits, staff training, and standardized quality systems can improve compliance (WHO, 2010; WHO, 2020).

9.9. Dependency on Imported APIs and Raw Materials
Dependence on imported APIs and key starting materials may expose pharmaceutical manufacturers to price fluctuations, geopolitical uncertainty, and international supply disruptions. Domestic manufacturing and supplier diversification are important strategies for improving supply security (Department of Pharmaceuticals, Government of India, 2020).

9.10. Natural Disasters, Pandemics, and Geopolitical Disruptions
Pandemics, natural disasters, conflicts, and trade restrictions can interrupt manufacturing and distribution activities. Emergency procurement plans, alternative suppliers, strategic stock, and business continuity planning can improve pharmaceutical supply chain resilience (Jaberidoost et al., 2013).

9.11. Limited Infrastructure in Rural and Remote Areas
Rural and remote regions may face inadequate transportation, limited storage facilities, unreliable electricity, and fewer healthcare distribution points. Improving regional warehouses, transportation connectivity, and digital inventory monitoring can strengthen medicine availability in these areas (WHO, 2020).

X. ROLE OF EMERGING TECHNOLOGIES IN DRUG SUPPLY CHAIN MANAGEMENT

Emerging technologies are transforming pharmaceutical supply chain management by improving product tracking, inventory accuracy, forecasting, transparency, and operational efficiency. Artificial Intelligence, IoT, blockchain, RFID, big data analytics, cloud computing, and robotics offer opportunities to develop more intelligent and interconnected distribution systems (Saeed et al., 2022).

10.1. Artificial Intelligence (AI)

AI can analyze historical consumption, market trends, and inventory information to improve demand forecasting and procurement planning. Machine learning algorithms may also help predict drug shortages, identify supply chain risks, and optimize inventory levels (Nabli et al., 2025).

10.2. Internet of Things (IoT)

IoT uses connected sensors and devices to collect and exchange real-time information. In pharmaceutical supply chains, IoT can monitor temperature, humidity, product location, and warehouse conditions. Automated alerts help identify environmental deviations and improve cold chain monitoring (Saeed et al., 2022).

10.3. Blockchain Technology

Blockchain provides a distributed and tamper-evident record of transactions. It may support medicine authentication, batch traceability, product recall management, and information sharing among supply chain stakeholders. Its effectiveness depends on reliable data entry, stakeholder participation, and system integration (Saeed et al., 2022).

10.4. Radio Frequency Identification (RFID)

RFID uses radio waves to identify and track pharmaceutical products through electronic tags and readers. It can improve stock tracking, product identification, warehouse automation, and inventory accuracy, while reducing dependence on manual scanning (Saeed et al., 2022).

10.5. Big Data Analytics

Big data analytics involves examining large datasets to identify consumption patterns, market trends, supplier performance, and distribution inefficiencies. It supports predictive decision-making and can improve procurement and logistics planning (Nabli et al., 2025).

10.6. Cloud-Based Supply Chain Management

Cloud-based platforms enable authorized stakeholders to access and share supply chain information through integrated digital systems. They can support electronic procurement, stock monitoring, shipment tracking, and coordination among manufacturers, distributors, and healthcare institutions (Saeed et al., 2022).

10.7. Robotics and Automation

Robotics and automation can improve pharmaceutical warehouse operations through automated storage, product picking, packaging, and inventory handling. These systems may reduce manual errors, improve productivity, and support faster order processing (Nabli et al., 2025).

Table 4. Emerging technologies and their applications

Technology	Major application
AI	Demand forecasting and shortage prediction
IoT	Real-time temperature monitoring
Blockchain	Product authentication and traceability
RFID	Automated identification and stock tracking
Big data	Predictive analysis and logistics optimization
Cloud computing	Integrated information sharing
Robotics	Automated warehouse operations

XI. PHARMACEUTICAL SUPPLY CHAIN MANAGEMENT IN INDIA

India has a large pharmaceutical manufacturing and distribution network that supplies medicines to domestic and international markets. The supply chain includes API manufacturers, formulation companies, wholesalers, distributors, hospitals, and retail pharmacies. Effective coordination among these stakeholders is essential for ensuring the availability, affordability, and quality of medicines (Department of Pharmaceuticals, Government of India, 2020).

11.1. Overview of the Indian Pharmaceutical Supply Chain

The Indian pharmaceutical supply chain involves the movement of medicines from manufacturers through carrying and forwarding agents, stockists, wholesalers, and retailers to the final patients. Public procurement agencies and government healthcare institutions also play an important role in medicine distribution.

11.2. Role of Pharmaceutical Manufacturers

Indian pharmaceutical manufacturers are responsible for producing APIs, formulations, and finished dosage forms. They manage raw material procurement, production, quality control, packaging, and distribution while complying with applicable regulatory requirements.

11.3. API Import Dependency and Domestic Manufacturing

Dependence on imported APIs and key starting materials may expose Indian pharmaceutical manufacturers to international supply disruptions and price fluctuations. The Government of India has introduced initiatives such as the Production Linked Incentive (PLI) Scheme for critical bulk drugs to encourage domestic manufacturing and improve supply security (Department of Pharmaceuticals, Government of India, 2020).

11.4. Role of Distributors, Wholesalers, and Retail Pharmacies

Distributors and wholesalers connect pharmaceutical manufacturers with hospitals and retail pharmacies. They are responsible for product storage, stock management, transportation, and timely supply. Retail pharmacies provide medicines directly to patients and contribute to medicine availability at the community level.

11.5. Government Initiatives for Medicine Availability

Government procurement programmes and domestic manufacturing initiatives support medicine availability and healthcare access. Effective procurement planning, quality assessment, and distribution monitoring are important for ensuring the timely supply of medicines to public healthcare institutions (Department of Pharmaceuticals, Government of India, 2020).

11.6. Role of Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP)

PMBJP is a Government of India initiative aimed at providing quality generic medicines at affordable prices through dedicated Janaushadhi Kendras. The programme seeks to reduce patients' medicine expenditure and improve access to essential medicines through an organized distribution network (Department of Pharmaceuticals, Government of India, 2026).

11.7. Digitalization of Pharmaceutical Distribution

Digital procurement, computerized inventory systems, electronic billing, and barcode-based tracking can improve pharmaceutical distribution in India. These technologies support stock monitoring, information exchange, and supply chain transparency (Saeed et al., 2022).

11.8. Challenges in Rural and Urban Drug Distribution

Urban distribution may be affected by traffic congestion, high demand, and fragmented distribution networks, whereas rural areas may face inadequate transportation, storage infrastructure, and electricity supply. Strengthening regional distribution networks and adopting digital inventory systems can improve medicine availability.

11.9. Opportunities for Strengthening India's Pharmaceutical Supply Chain

India can strengthen its pharmaceutical supply chain through domestic API manufacturing, supplier diversification, improved warehousing, cold chain infrastructure, and digital transformation. Better collaboration among government agencies, manufacturers, distributors, and healthcare institutions can further improve supply chain resilience (Jaberidoost et al., 2013).

XII. STRATEGIES FOR IMPROVING PHARMACEUTICAL SUPPLY CHAIN EFFICIENCY

Improving pharmaceutical supply chain efficiency requires effective procurement, inventory optimization, quality management, digital integration, and risk management. These strategies help reduce

operational costs, prevent medicine shortages, and maintain product quality throughout distribution (Jaberidoost et al., 2013; Uthayakumar and Priyan, 2013).

12.1. Supplier Diversification

Obtaining raw materials from multiple qualified suppliers reduces dependency on a single source and minimizes the risk of procurement disruptions. Supplier evaluation and regular quality audits are essential for maintaining reliability (Jaberidoost et al., 2013).

12.2. Strategic Procurement Planning

Systematic procurement planning involves evaluating medicine requirements, supplier performance, purchase schedules, and available budgets. Effective procurement can reduce purchasing costs and support continuous material availability (Uthayakumar and Priyan, 2013).

12.3. Demand Forecasting

Demand forecasting uses historical consumption, market trends, and seasonal variations to estimate future medicine requirements. Accurate forecasting helps organizations plan production, procurement, and inventory levels (Nabli et al., 2025).

12.4. Inventory Optimization

Inventory optimization involves maintaining appropriate stock levels while minimizing holding costs, wastage, and shortages. ABC–VED analysis, EOQ, safety stock, FEFO, and computerized inventory systems can improve stock management (Uthayakumar and Priyan, 2013).

12.5. Integrated Digital Supply Chain Systems

Integration of ERP, WMS, TMS, and cloud-based platforms can improve communication and information sharing among supply chain stakeholders. Digital systems support real-time stock monitoring, order processing, and product tracking (Saeed et al., 2022).

12.6. Improved Warehouse Infrastructure

Modern warehouses should provide appropriate temperature control, humidity monitoring, security, cleanliness, and inventory tracking. Automated systems and regular equipment maintenance can improve storage efficiency and product protection (WHO, 2020).

12.7. Cold Chain Strengthening

Qualified refrigeration equipment, insulated packaging, temperature data loggers, and trained personnel are necessary for maintaining the quality of temperature-sensitive medicines. Preventive maintenance and monitoring help reduce temperature excursions (WHO, 2011).

12.8. Risk Management and Contingency Planning

Risk assessment, alternative suppliers, emergency stock, and business continuity planning help organizations manage unexpected supply disruptions. These measures are particularly important for essential medicines and critical APIs (Jaberidoost et al., 2013).

12.9. Collaboration Between Manufacturers, Distributors, and Healthcare Institutions

Effective information sharing and coordination among manufacturers, distributors, hospitals, and pharmacies improve demand planning and medicine availability. Collaborative forecasting and regular stock monitoring can reduce supply chain inefficiencies (Uthayakumar and Priyan, 2013).

12.10. Sustainable Pharmaceutical Logistics

Optimized transportation routes, energy-efficient warehouses, appropriate packaging, and effective waste management can reduce the environmental impact of pharmaceutical distribution while maintaining product quality (WHO, 2020).

XIII. SUSTAINABILITY AND GREEN PHARMACEUTICAL SUPPLY CHAIN

A green pharmaceutical supply chain integrates environmental protection into procurement, manufacturing, packaging, storage, transportation, and waste management. Its main objective is to reduce resource consumption, waste generation, and environmental pollution while maintaining medicine quality and patient safety (WHO, 2020).

13.1. Environmentally Responsible Drug Transportation

Route optimization, efficient vehicle utilization, and fuel-efficient transportation can reduce fuel consumption and greenhouse gas emissions.

Sustainable transportation practices should maintain the required storage conditions for pharmaceutical products.

13.2. Sustainable Packaging

Reducing unnecessary packaging materials and using recyclable materials where appropriate can minimize pharmaceutical packaging waste. Packaging modifications must maintain product stability, protection, and regulatory compliance.

13.3. Pharmaceutical Waste Management

Pharmaceutical waste includes expired medicines, damaged products, rejected batches, and unused formulations. Proper segregation, collection, treatment, and disposal are necessary to prevent environmental contamination and accidental reuse (WHO, 2020).

13.4. Reverse Logistics

Reverse logistics involves returning expired, damaged, recalled, or defective medicines from pharmacies, hospitals, and distributors to authorized collection or disposal facilities. It supports product recall management and prevents unsuitable medicines from re-entering the distribution network (WHO, 2020).

13.5. Energy-Efficient Warehouses

Energy-efficient lighting, improved insulation, modern refrigeration systems, and renewable energy sources can reduce warehouse energy consumption. Proper maintenance is necessary to ensure that energy-saving measures do not compromise pharmaceutical storage conditions.

13.6. Reduction of Carbon Emissions

Carbon emissions can be reduced through optimized transportation, efficient warehousing, reduced packaging waste, and renewable energy adoption. Monitoring environmental performance can help pharmaceutical organizations identify opportunities for improvement.

13.7. Safe Disposal and Management of Expired Medicines

Expired medicines should be segregated from saleable inventory and disposed of through authorized procedures. Proper disposal helps prevent accidental consumption, unauthorized reuse, and environmental contamination (WHO, 2020).

XIV. FUTURE PERSPECTIVES

The future of pharmaceutical supply chain management will increasingly depend on digital transformation, automation, predictive analytics, and sustainable distribution systems. Integration of emerging technologies may improve product traceability, inventory management, supply chain visibility, and medicine availability (Saeed et al., 2022; Nabli et al., 2025).

14.1. AI-Driven Intelligent Pharmaceutical Supply Chains

AI-based systems may improve demand forecasting, procurement planning, inventory optimization, and drug shortage prediction. Future research should evaluate their accuracy, reliability, and practical effectiveness in pharmaceutical distribution.

14.2. Blockchain-Enabled Drug Traceability

Blockchain may provide secure and traceable records of pharmaceutical product movement, helping improve authentication, transparency, and recall management (Saeed et al., 2022).

14.3. Fully Integrated Digital Supply Chain Platforms

Integrated digital platforms connecting manufacturers, distributors, hospitals, and pharmacies may improve real-time information exchange, stock monitoring, and distribution planning.

14.4. Predictive Drug Shortage Management

Predictive analytical systems may identify medicines at risk of shortage by evaluating demand, inventory, supplier reliability, and manufacturing information. Early identification can support timely procurement and contingency planning (Nabli et al., 2025).

14.5. Smart Warehouses and Automated Distribution

Robotics, RFID, IoT sensors, and automated storage systems may improve product handling, stock accuracy, packaging, and order fulfillment in pharmaceutical warehouses.

14.6. Patient-Centric Medicine Delivery

Future supply chains may increasingly focus on timely and affordable medicine delivery through digital

prescriptions, integrated pharmacy systems, and patient-centered distribution models. Appropriate dispensing, storage, and patient safety must remain priorities.

14.7. Sustainable and Resilient Pharmaceutical Supply Chain Models

Future supply chain models should combine supplier diversification, domestic manufacturing, digital technologies, efficient logistics, and environmentally responsible practices. Such approaches may improve resilience against pandemics, natural disasters, and geopolitical disruptions (Jaberidoost et al., 2013; WHO, 2020).

14.8. Opportunities for Research and Technological Development

Further research is required to evaluate AI-based forecasting, IoT-enabled cold chain monitoring, blockchain traceability, and sustainable pharmaceutical distribution. Studies should also assess implementation costs, regulatory acceptance, data security, and suitability for resource-limited healthcare settings (Saeed et al., 2022; Nabli et al., 2025).

XV. CONCLUSION.

The present review highlights that effective pharmaceutical supply chain management is essential for ensuring the timely availability, quality, safety, and affordability of medicines. It demonstrates that proper coordination of procurement, manufacturing, inventory management, storage, transportation, and distribution can minimize medicine shortages, reduce wastage, and improve operational efficiency. However, challenges such as counterfeit medicines, poor infrastructure, temperature-control issues, regulatory barriers, and supply disruptions continue to affect the reliability of pharmaceutical supply chains. The integration of emerging technologies, including artificial intelligence, IoT, blockchain, RFID, and data analytics, can improve transparency, traceability, forecasting, and decision-making. In countries like India, strengthening domestic manufacturing, distribution infrastructure, inventory systems, and regulatory practices is particularly important. Sustainable logistics and efficient cold-chain management are also necessary to reduce environmental impact and maintain medicine quality. Overall, the future of pharmaceutical supply chain management depends on an integrated, technology-enabled, resilient, and sustainable approach that ensures uninterrupted access to safe, effective, and affordable medicines for patients.

REFERENCE

[1] M. Jaberidoost, S. Nikfar, A. Abdollahiasl, and R. Dinarvand, “Pharmaceutical supply chain risks: A systematic review,” *DARU*, vol. 21, Art. no. 69, 2013, doi: 10.1186/2008-2231-21-69.

[2] R. Uthayakumar and S. Priyan, “Pharmaceutical supply chain and inventory management strategies: Optimization for a pharmaceutical company and a hospital,” *Operations Research for Health Care*, vol. 2, no. 3, pp. 52–64, 2013, doi: 10.1016/j.orhc.2013.08.001.

[3] N. Yousefi and A. Alibabaei, “Information flow in the pharmaceutical supply chain,” *Iranian Journal of Pharmaceutical Research*, vol. 14, no. 4, pp. 1299–1303, 2015, doi: 10.22037/ijpr.2015.1764.

[4] World Health Organization, *WHO Good Distribution Practices for Pharmaceutical Products*, WHO Technical Report Series No. 957, Annex 5. Geneva, Switzerland: WHO, 2010.

[5] World Health Organization, *WHO Good Storage and Distribution Practices for Medical Products*, WHO Technical Report Series No. 1025, Annex 7. Geneva, Switzerland: WHO, 2020.

[6] World Health Organization, “WHO work on supply systems,” Geneva, Switzerland: WHO, 2015. [Online]. Available: https://www.who.int/teams/health-product-policy-and-standards/medicines-selection-ip-and-affordability/medicines-policy/medicines-supply

[7] R. L. Mendoza, “Continuity and change in the drug supply chain: Actors, actions, and aversions,” *Journal of Medical Economics*, vol. 24, no. 1, pp. 689–697, 2021, doi: 10.1080/13696998.2021.1925123.

[8] M. Wadhwa, P. Trivedi, D. Raval, S. Saha, H. Prajapati, R. Gautam, et al., “Factors affecting

the availability and utilization of essential medicines in India: A systematic review," *Journal of Pharmacy and Bioallied Sciences*, vol. 16, suppl. 2, pp. S1064–S1071, 2024, doi: 10.4103/jpbs.jpbs_1198_23.

[9] Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India, "India's dependence on imported APIs," Press Information Bureau, 2026. [Online]. Available: https://www.pib.gov.in/PressReleasePage.aspx?PRID=2222528&lang=1&reg=3

[10] M. Jaberidoost, S. Nikfar, A. Abdollahiasl, and R. Dinarvand, "Pharmaceutical supply chain risks: A systematic review," *DARU*, vol. 21, Art. no. 69, 2013, doi: 10.1186/2008-2231-21-69.

[11] R. Uthayakumar and S. Priyan, "Pharmaceutical supply chain and inventory management strategies: Optimization for a pharmaceutical company and a hospital," *Operations Research for Health Care*, vol. 2, no. 3, pp. 52–64, 2013, doi: 10.1016/j.orhc.2013.08.001.

[12] N. Yousefi and A. Alibabaei, "Information flow in the pharmaceutical supply chain," *Iranian Journal of Pharmaceutical Research*, vol. 14, no. 4, pp. 1299–1303, 2015, doi: 10.22037/ijpr.2015.1764.

[13] World Health Organization, *WHO Good Storage and Distribution Practices for Medical Products*, WHO Technical Report Series No. 1025, Annex 7. Geneva, Switzerland: WHO, 2020.

[14] World Health Organization, *WHO Good Distribution Practices for Pharmaceutical Products*, WHO Technical Report Series No. 957, Annex 5. Geneva, Switzerland: WHO, 2010.

[15] World Health Organization, "WHO guidelines on quality assurance of pharmaceutical products and distribution," Geneva, Switzerland: WHO. [Online]. Available: https://www.who.int/teams/health-product-and-policy-standards/standards-and-specifications/norms-and-standards-for-pharmaceuticals/guidelines/distribution

[16] M. Jaberidoost, S. Nikfar, A. Abdollahiasl, and R. Dinarvand, "Pharmaceutical supply chain risks: A systematic review," *DARU Journal of Pharmaceutical Sciences*, vol. 21, Art. no. 69, 2013, doi: 10.1186/2008-2231-21-69.

[17] R. Uthayakumar and S. Priyan, "Pharmaceutical supply chain and inventory management strategies: Optimization for a pharmaceutical company and a hospital," *Operations Research for Health Care*, vol. 2, no. 3, pp. 52–64, 2013, doi: 10.1016/j.orhc.2013.08.001.

[18] S. Priyan and R. Uthayakumar, "Optimal inventory management strategies for pharmaceutical company and hospital supply chain in a fuzzy-stochastic environment," *Operations Research for Health Care*, vol. 3, no. 4, pp. 177–190, 2014, doi: 10.1016/j.orhc.2014.08.001.

[19] World Health Organization, *WHO Good Distribution Practices for Pharmaceutical Products*, WHO Technical Report Series No. 957, Annex 5. Geneva, Switzerland: WHO, 2010.

[20] World Health Organization, *Model Guidance for the Storage and Transport of Time- and Temperature-Sensitive Pharmaceutical Products*, WHO Technical Report Series No. 961, Annex 9. Geneva, Switzerland: WHO, 2011.

[21] World Health Organization, *WHO Good Manufacturing Practices for Pharmaceutical Products: Main Principles*, WHO Technical Report Series No. 986, Annex 2. Geneva, Switzerland: WHO, 2014.

[22] World Health Organization, *Technical Supplements to Model Guidance for the Storage and Transport of Time- and Temperature-Sensitive Pharmaceutical Products*, WHO Technical Report Series No. 992, Annex 5. Geneva, Switzerland: WHO, 2015.

[23] World Health Organization, *Good Storage and Distribution Practices for Medical Products*, WHO Technical Report Series No. 1025, Annex 7. Geneva, Switzerland: WHO, 2020.

[24] World Health Organization, *Substandard and Falsified Medical Products*. Geneva, Switzerland: WHO, 2024.

[25] G. Saeed, J. C. Kohler, R. E. Cuomo, and T. K. Mackey, "A systematic review of digital

technology and innovation and its potential to address anti-corruption, transparency, and accountability in the pharmaceutical supply chain," *Expert Opinion on Drug Safety*, vol. 21, no. 8, pp. 1061–1088, 2022, doi: 10.1080/14740338.2022.2091543.

[26] H. Nabli, A. Ghannem, R. Ben Djemaa, and L. Sliman, "How innovative technologies shape the future of pharmaceutical supply chains," *Computers & Industrial Engineering*, Art. no. 110745, 2025, doi: 10.1016/j.cie.2024.110745.

[27] Government of India, *The Drugs and Cosmetics Act, 1940*. Ministry of Health and Family Welfare, Government of India.

[28] Government of India, *The Drugs Rules, 1945*. Ministry of Health and Family Welfare, Government of India.

[29] Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India, *Production Linked Incentive Scheme for Promotion of Domestic Manufacturing of Critical Key Starting Materials, Drug Intermediates and Active Pharmaceutical Ingredients*, 2020.